This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression	Phosphodiesterase-4 (PDE4A; PDE-4), 5-hydroxytryptamine (serotonin) receptor (HTR; 5-HT)	<p>A study in mice suggests that dual inhibitors of PDE-4 and HTR may be more efficacious depression therapeutics than either inhibitor alone. In mice, a dual inhibitor significantly decreased immobility in a forced-swim test compared with that seen in vehicle-treated controls ($p < 0.05$). Next steps include efficacy and toxicology studies in animal models.</p> <p>Multiple selective serotonin reuptake inhibitors (SSRIs) are marketed to treat psychiatric disorders.</p> <p>SciBX 2(11); doi:10.1038/scibx.2009.463 Published online March 19, 2009</p>	Patent application filed covering compounds; available for licensing	<p>Cashman, J.R. <i>et al. J. Med. Chem.</i>; published online March 3, 2009; doi:10.1021/jm8010993</p> <p>Contact: John R. Cashman, Human BioMolecular Research Institute, San Diego, Calif. e-mail: jcashman@hbri.org</p>